Please login to the form below
nusinersen
This page shows the latest nusinersen news and features for those working in and with pharma, biotech and healthcare.
Genentech shares positive two-year data for Evrysdi in spinal muscular atrophy study
Participants had been previously treated with other approved or investigational SMA-targeting therapies, including Spinraza (nusinersen) or Zolgensma (onasemnogene abeparvovec).
Latest news
-
Biogen pays Ionis $60m for licence to develop ASO for spinal muscular atrophy
intervals. “Combining Biogen’s expertise in neurology with Ionis’ leadership in antisense technology has led to Spinraza (nusinersen) being a foundation of care in SMA,” said Toby Ferguson, vice president and
-
AstraZeneca and Ionis sign $3.6bn deal for eplontersen
It currently has three marketed products – Spinraza (nusinersen) for spinal muscular atrophy, Tegsedi (inotersen) for ATTR and Waylivra (volanesorsen) for familial chylomicronaemia syndrome – as well as ‘a premier late-stage pipeline’.
-
UK’s NICE recommends Roche’s Evrysdi
Other therapies are available to treat SMA, including Biogen’s Spinraza (nusinersen) and Novartis’ gene therapy Zolgensma (onasemnogene abeparvovec).
-
Biogen reports new data backing long-term benefit of Spinraza
This includes new analysis of data from Biogen’s NURTURE study, which showed 92% of patients who started Spinraza (nusinersen) treatment as pre-symptomatic infants maintained the ability to swallow after
-
EU authorises Roche’s spinal muscular atrophy treatment Evrysdi
Evrysdi becomes the third drug approved to treat the condition, following Biogen's Spinraza (nusinersen) and Novartis' Zolgensma (onasemnogene abeparvovec), and is the first that can be administered orally.
More from news
Approximately 4 fully matching, plus 43 partially matching documents found.
Latest Intelligence
-
Deal Watch August 2016
95. Ionis (US). Biogen (US). Exercise option . Nusinersen, in phase III for treatment for spinal muscular atrophy.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Article: Market access in Brazil
In April 2019, Brazilian Health Minister Luiz Henrique Mandetta announced a pilot agreement for access to Biogen’s Spinal Muscular Atrophy (SMA) treatment Spinraza (nusinersen) through the Sistema Único de Saúde
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- AstraZeneca and Daiichi Sankyo share positive results from phase 3 breast cancer study
- ICR and Merck renew strategic alliance for development of new cancer drugs
- DeepMind’s AI tool classifies effects of mutations in genetic diseases
- CDC awards over $23m to Johns Hopkins Center for Health Security project
- Looking to start activity on a currently unpromoted pharmaceutical brand?
- Considering a portfolio review?
No results were found
PMHub
Genesis Research
Genesis Research is an international HEOR and RWE research organization. A leader in evidence strategy, generation and communication, the company...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
